Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint to Identify Genetic Markers for NYU Transplant Center


NEW YORK, Dec. 3 – DNAPrint Genomics of Sarasota, Fla., said Monday that it had entered an agreement with the New York University School of Medicine to identify genetic markers that can help determine how recipients of kidney transplants will respond to certain drugs. 

Under the terms of the deal, NYU's Mary Lea Johnson Richards Organ Transplantation Center will provide DNAPrint with patient samples and clinical data from patients. DNAPrint will use its genotyping technologies and SNP database to screen the specimens for markers. 

“The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture,” DNAPrint said in a statement.

The company estimated that the project would take about one year to complete.

Financial terms of the deal were not disclosed.

In August, DNAPrint Genomics announced a deal to study specimens provided by Pharsight of Mountain View, Calif., to determine which genetic markers are responsible for patients' varying responses to drugs designed to treat metabolic disorders.


The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.